Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Drops By 30.4%

Ventyx Biosciences, Inc. (NASDAQ:VTYX) saw a large drop in short interest in January. As of January 15th, there was short interest totalling 6,680,000 shares, a drop of 30.4% from the December 31st total of 9,600,000 shares. Currently, 12.6% of the company’s stock are sold short. Based on an average trading volume of 1,750,000 shares, the short-interest ratio is presently 3.8 days.

Insiders Place Their Bets

In other Ventyx Biosciences news, Director Sheila Gujrathi acquired 130,000 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $2.31 per share, for a total transaction of $300,300.00. Following the completion of the purchase, the director now directly owns 130,000 shares in the company, valued at $300,300. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Raju Mohan bought 261,752 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was bought at an average price of $2.01 per share, with a total value of $526,121.52. Following the completion of the purchase, the chief executive officer now owns 2,175,028 shares of the company’s stock, valued at $4,371,806.28. This trade represents a 13.68 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 630,000 shares of company stock valued at $1,262,415 in the last ninety days. Corporate insiders own 18.18% of the company’s stock.

Institutional Investors Weigh In On Ventyx Biosciences

Institutional investors have recently bought and sold shares of the stock. Catalina Capital Group LLC bought a new stake in shares of Ventyx Biosciences in the 4th quarter worth $25,000. Palumbo Wealth Management LLC acquired a new position in Ventyx Biosciences during the third quarter worth about $26,000. China Universal Asset Management Co. Ltd. raised its position in Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after acquiring an additional 5,310 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Ventyx Biosciences in the 3rd quarter valued at about $42,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after purchasing an additional 7,096 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Stock Down 2.0 %

Ventyx Biosciences stock traded down $0.04 during mid-day trading on Friday, hitting $2.01. 1,124,738 shares of the company’s stock traded hands, compared to its average volume of 1,759,177. Ventyx Biosciences has a one year low of $1.67 and a one year high of $11.48. The company has a market cap of $142.13 million, a PE ratio of -0.85 and a beta of 0.55. The firm has a 50 day moving average price of $2.31 and a 200 day moving average price of $2.25.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. HC Wainwright restated a “neutral” rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th. Oppenheimer reissued an “outperform” rating and set a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.